Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor).
Siddiqui BA, Chapin BF, Jindal S, Duan F, Basu S, Yadav SS, Gu AD, Espejo AB, Kinder M, Pettaway CA, Ward JF, Tidwell RSS, Troncoso P, Corn PG, Logothetis CJ, Knoblauch R, Hutnick N, Gottardis M, Drake CG, Sharma P, Subudhi SK.
Siddiqui BA, et al. Among authors: gu ad.
J Immunother Cancer. 2023 Mar;11(3):e006262. doi: 10.1136/jitc-2022-006262.
J Immunother Cancer. 2023.
PMID: 36948506
Free PMC article.